Premium
Sustained first remission in an adolescent with hepatosplenic T‐cell lymphoma treated with T‐cell leukemia induction, nucleoside analog‐based consolidation, and early hematopoietic stem cell transplant
Author(s) -
Schafer Eric,
Chen Allen,
Arceci Robert J.
Publication year - 2009
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.22129
Subject(s) - medicine , lymphoma , leukemia , oncology , chemotherapy , hematopoietic stem cell transplantation , regimen , stem cell , transplantation , nucleoside analogue , haematopoiesis , immunology , cancer research , nucleoside , genetics , stereochemistry , chemistry , biology
Hepatosplenic T‐cell lymphoma (HTCL) is a rare malignancy. Prognosis is poor with only a few case reports of long‐term survivors. While HTCL universally involves the bone marrow, the condition has been most often treated with multimodal lymphoma specific chemotherapy. We report a durable, sustained first remission in an adolescent treated for HTCL who received induction therapy according to a high risk T‐cell leukemia regimen, a nucleoside analog‐based consolidation, and allogeneic transplantation associated with GVHD. Pediatr Blood Cancer 2009;53:1127–1129. © 2009 Wiley‐Liss, Inc.